CD5 Expression on B Cells May Be an Activation Marker for Secretion of Anti-myelin Antibodies in Patients with Polyneuropathy Associated with Monoclonal Gammopathy
Overview
Authors
Affiliations
B cells expressing the CD5 marker belong to a subpopulation with potential autoreactive properties. Increased proportions of CD5+ B cells have been reported in autoimmune diseases. In patients with monoclonal gammopathy and demyelinating polyneuropathy, the M-component often consists of autoantibodies reacting with myelin components. We therefore investigated if CD5+ B cells were involved in the production of anti-myelin antibodies. There was no difference of mean value of CD5+ B cells between patients and controls. However, the proportion of CD5+ B cells was significantly correlated with the amount of anti-myelin antibodies. In seven patients, CD5+ B cells were enriched using an immunomagnetic technique. The number of CD5+ and CD5- B cells secreting anti-myelin antibodies was determined by ELISPOT. In two patients with high levels of antibodies, antibody-secreting cells were mainly, but not exclusively, CD5+ B cells. In five patients with low levels of antibodies, most cells secreting anti-myelin antibodies were CD5-. We conclude that CD5 expressed on B cells may be an activation marker, reflecting B cells producing high amounts of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.
Kvarnstrom M, Sidorova E, Nilsson J, Ekerfelt C, Vrethem M, Soderberg O Clin Exp Immunol. 2002; 127(2):255-62.
PMID: 11876747 PMC: 1906329. DOI: 10.1046/j.1365-2249.2002.01739.x.